Lifecore Biomedical, Inc. (LFCR)
NASDAQ: LFCR · Real-Time Price · USD
7.28
-0.21 (-2.80%)
Dec 27, 2024, 4:00 PM EST - Market closed
Lifecore Biomedical Revenue
Lifecore Biomedical had revenue of $24.71M in the quarter ending August 25, 2024, with 0.75% growth. This brings the company's revenue in the last twelve months to $128.44M, up 23.42% year-over-year. In the fiscal year ending May 26, 2024, Lifecore Biomedical had annual revenue of $128.26M with 24.20% growth.
Revenue (ttm)
$128.44M
Revenue Growth
+23.42%
P/S Ratio
1.73
Revenue / Employee
$245,122
Employees
524
Market Cap
268.10M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| May 26, 2024 | 128.26M | 24.99M | 24.20% |
| May 28, 2023 | 103.27M | -8.00M | -7.19% |
| May 29, 2022 | 111.27M | 10.40M | 10.31% |
| May 30, 2021 | 100.87M | -59.19M | -36.98% |
| May 31, 2020 | 160.07M | -397.49M | -71.29% |
| May 26, 2019 | Pro | Pro | Pro |
| May 27, 2018 | Pro | Pro | Pro |
| May 28, 2017 | Pro | Pro | Pro |
| May 29, 2016 | Pro | Pro | Pro |
| May 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Procaps Group | 414.10M |
| OraSure Technologies | 224.26M |
| Vanda Pharmaceuticals | 190.86M |
| Foghorn Therapeutics | 25.52M |
| Senseonics Holdings | 22.21M |
| ProQR Therapeutics | 20.51M |
| aTyr Pharma | 235.00K |
LFCR News
- 3 days ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Reach Out - Accesswire
- 5 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect - Accesswire
- 8 days ago - Lifecore Biomedical to Report Financial Results for Second Quarter of Fiscal 2025 on January 2, 2025 - GlobeNewsWire
- 8 days ago - Lifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment - GlobeNewsWire
- 9 days ago - Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Accesswire
- 12 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Stockholders to Learn More About the Investigation - Accesswire
- 16 days ago - Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Investors to Inquire about Securities Investigation - Accesswire
- 26 days ago - Lifecore Biomedical: An Interesting CDMO Pure Play - Seeking Alpha